Home / Uncategorized / GenSight Biologics Announces Publication of Positive Safety Data from Phase I/II Trial of GS010 in the JAMA Ophthalmology

GenSight Biologics Announces Publication of Positive Safety Data from Phase I/II Trial of GS010 in the JAMA Ophthalmology

Business Wire – PARIS — –Feb 12, 2019–Regulatory News:
Source: New feed

About bingpedia

Check Also

US Justice Department sends out email with content from antisemitic blog

Jerusalem Post – According to the Washington Post, the post included in the memo singled …

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: